Anavex Life Sciences Corp (AVXL)

[frrol]

Your "analysis" is poor and misleads. Be careful. I'll provide a few examples of the latest mistakes.

"...Anavex confirms that the trial was a success by one of two methods, both methods of which measure mean changes between dosed cohorts and placebo [different than odds ratio computations displayed at CTAD 22].
Method A: All 3x primary and secondary endpoints (ADAS-COG13, ADCS-ADL, and CDR-SB) produced P-values of at least 0.05 indicating statistical significance."

Method A was not by mean changes for the 3 endoints. The ADCS-ADL endpoint was by odds risk. And your first sentence is misleading. Do you see how?

"It is more likely that the ADCS-ADL P-value is somewhere between 0.025 and 0.05 and thus the company chose to disclose the two more enticing statistical measures."

This is not reasoning, this is confirmation bias. A biotech doesn't omit a potentially pivotal trial's successful co-primary endpoint.

"The odds ratio data actually indicates that ADCS-ADL performed more spectacularly than ADAS-COG..."

"More spectacularly" is nonsense mathematically. A high-threshold OR of approx 2.7 is just good, because it is a bit over 1. I've explained why a couple times before, so won't repeat. You need to review the explanation, or learn the math behind ORs on your own.

There's many more. You invest a lot of time in these. Be sure to understand the results and review what you write to make it credible. Focus on being correct, not positive, to minimize confirmation bias.